Pharma Sector

Pharmaceutical sector set to gain from rupee fall despite API dependence

Exporters like Sun Pharma, Dr Reddy's may see 7-8% revenue lift, yet margins pressured by high raw material import costs

UK, US sign zero-tariff pharma deal in exchange for higher drug spending

The UK has sealed a deal securing a 0 per cent tariff rate for all UK medicines exported to the US for at least 3 years, officials said Monday, in return for the UK spending more on new medicines. Under the deal, announced by officials on both sides, the United States government agreed to exempt UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from import taxes. The Trump administration said that in return, UK drugs firms committed to invest more in the US and create more jobs. As part of the deal, the UK government said it will invest around 25 per cent more in new and effective treatments the first major increase in such spending in over two decades. Both sides hailed the deal as a win. This vital deal will ensure UK patients get the cutting-edge medicines they need sooner, and our world-leading UK firms keep developing the treatments that can change lives, Science and Technology Secretary Liz Kendall said. US Health Secretary Robert F. Kennedy Jr.

Cipla launches India's first integrated lung diagnostics, wellness centre

The Delhi facility offers over 60 advanced tests and aims to close critical gaps in respiratory diagnosis and care

CDSCO committee considers avoiding high-risk solvents in kids' oral drugs

Following the Chhindwara cough syrup tragedy, a CDSCO committee has advised consultations to phase out high-risk solvents in oral formulations

Generic drugmakers to slash price plans as Novo cuts Wegovy rates

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

CDSCO panel seeks uniform enforcement of drug standards across states

The DCC has asked the Centre to address gaps in drug-standard enforcement, write to states on non-uniform norms and improve testing and regulatory infrastructure highlighted under the SHRESTH index

Zydus Lifesciences, RK Pharma sign deal for licensing, commercialisation

Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing. The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added. "This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said. RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and

SMS Pharma up 8% as arm gets USFDA nod for reformulated Ranitidine tablets

At 10:40 AM, SMS Pharmaceuticals share price was trading 6.77 per cent higher at ₹292.55 per share. In comparison, BSE Sensex was trading 0.73 per cent higher at 85,204.25 levels.

18 nations and rising: India builds global support for its Pharmacopoeia

Industry representatives argue that global acceptance of Indian Pharmacopoeia could significantly reduce export costs and make Indian drugs more affordable to developing nations

Eris Lifesciences to acquire 30% stake in Swiss Parenterals for ₹423 cr

Eris Lifesciences will purchase the final 30% stake in Swiss Parenterals through a Rs 423-crore share swap, aiming for full consolidation, greater cost efficiency and strengthened strategic control

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Sudeep Pharma IPO subscribed 5.09 times on Day 2; NII bids hit 12x

The initial public offer of Sudeep Pharma Ltd received 5.09 times subscription on the second day of bidding on Monday. The IPO received bids for 5,37,83,650 shares against 1,05,64,926 shares on offer, according to NSE data. The category for non-institutional investors fetched 12 times subscription, while the quota for Retail Individual Investors (RIIs) got subscribed 4.96 times. The Qualified Institutional Buyers (QIBs) portion received 13 per cent subscription. Sudeep Pharma on Thursday said it has mobilised Rs 268.5 crore from anchor investors. The Rs 895 crore initial public offering (IPO) will conclude on Tuesday. The price band has been fixed at Rs 563-593 per equity share. The IPO has a fresh issue of equity shares worth Rs 95 crore and an offer-for-sale of nearly 1.35 crore equity shares, aggregating to Rs 800 crore, by the promoters. Proceeds from the fresh issue to the tune of Rs 75.81 crore will be used for capital expenditure towards the procurement of machinery for it

Aurobindo incurring loss at China Plant, hopes to achieve break-even by Q4

Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the end of the fiscal year, according to its CFO S Subramanian. The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses, he said. "China (plant), as on date in the quarter, I will be incurring a loss of around maybe a million dollars, but, probably, we will be able to achieve the break-even between Q3 and Q4 and after that, China will start moving up in the overall contributing to the growth of the EBITDA growth," Subramanian said in an analyst call. The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals, he stated. The site is on track to deliver EBITDA break-even by Q3-Q4 FY26, reinforcing its strategic importance to the global network, he added.

Elderly may account for 25% of India's pharma market in 2-3 decades

Seniors are 10% of India, but already 17% of its pharma market

Mankind Pharma inks licencing pact with Actimed for cachexia treatment

Mankind Pharma has entered a licensing agreement with Actimed Therapeutics to develop and commercialise cachexia treatment products across India and neighbouring South Asian markets

People should get proper remedy against pharma firms' malpractices: SC

The Supreme Court on Tuesday said procedures under the uniform code for pharmaceutical marketing should be so strong that any consumer who is cheated should have access and proper remedy against unethical practices. A bench of justices Vikram Nath and Sandeep Mehta observed there should be appropriate measures where the consumers have a convenient mechanism for lodging their complaints and ensuring that action is taken against erring companies. The top court was hearing a plea seeking that the uniform code of pharmaceutical marketing practices should curb alleged unethical practices of pharma firms. Additional Solicitor General K M Nataraj, appearing for the Centre, said the government has introduced several policies for the purpose of either restricting the pricing of medicines and to regulate such activities. He referred to the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP), 2024, which prohibits pharma companies from offering gifts and travel facilities to healthca

India and China begin discussions for a reverse-trade model for drugs

This would unlock export potential of $6 billion for Indian pharma companies

IPC, Jharkhand Pharmacy Council sign MoU to boost pharmacovigilance, safety

The Indian Pharmacopoeia Commission (IPC), Ghaziabad, on Saturday inked an MoU with the Jharkhand State Pharmacy Council (JSPC) to promote safe and rational medicine use and strengthen pharmacovigilance in Jharkhand. The Indian Pharmacopoeia Commission (IPC), Ghaziabad, is an autonomous institution under the Union Health Ministry. Through this collaboration, IPC and JSPC will work together to build the capacity of registered pharmacists in areas related to adverse drug reaction (ADR) reporting, pharmacovigilance and materiovigilance practices, and the safe use of medicines, a health ministry statement said. The partnership envisions strengthening the utilisation of the National Formulary of India (NFI) as a standard reference document across healthcare facilities in Jharkhand and promoting its systematic use by pharmacists to support rational dispensing and safe medication practices. It further includes coordinated efforts to organise awareness programmes for hospital and community

Akums Q2 PAT falls 35.8% on muted CDMO biz growth, declining API prices

Despite this, the CDMO segment remained Akums' key growth driver, contributing Rs 804 crore, or 79 per cent of its total revenue

Lupin share rises 2% as arm commissions Oncology block at Vizag facility

At 1:15 PM, Lupin share price was trading 1.90 per cent higher at ₹2,013.20 per share. In comparison, BSE Sensex was trading 0.91 per cent higher at 84,632.82 levels.